Eric A. Collisson, MD
Heterogeneity, diagnostics, and molecular profiling are examples of the clinical challenges in treating patients with cholangiocarcinoma, explained Eric A. Collisson, MD, but targeting FGFR2
could be a potential approach in improving outcomes.
“One of the themes in gastrointestinal (GI) oncology is the specialized development of these therapeutics,” said Collisson. “There are some specific challenges that each one of these different diseases hold in getting drugs approved and using them safely and effectively.”
... to read the full story